Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Travere Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
134
155
164
175
198
132
109
145
233
491
Cost of revenue
4.55
3.61
5.53
5.23
6.13
3.82
4.42
11.5
7.74
10.3
Gross profit
129
151
159
170
192
128
105
134
225
480
Research and development
70.8
78.2
124
141
132
201
7.5
245
217
206
Selling, general and administrative
91.9
101
104
129
136
126
198
266
264
337
Operating expenses
192
209
244
Operating income
-58.2
-53.8
-80
-137
-176
-199
-320
-388
-324
-62.8
Interest expense
4.73
4.42
9.81
18.8
19.1
19.7
11
11.3
11.2
10.7
Interest income
3.23
5.5
10.1
5
1.99
6.28
21.8
17.8
12.7
Other non-operating income
0.63
-4.57
-21.8
-9.09
-12.6
-17.5
-11.3
12
3.32
13.6
Pre-tax income
-57.6
-58.4
-102
-146
-189
-217
-331
-376
-321
-49.3
Income tax
-9.68
1.37
0.81
-0.02
-19.4
0.41
0.31
0.22
0.12
0.99
Income from continuing operations
-217
-331
-376
-321
-50.3
Net income
-47.9
-59.7
-103
-146
-169
-180
-278
-111
-322
-25.5
EBITDA
-42.1
-36
-61.4
-117
-152
-187
-299
-350
-280
-2.08
EPS, basic
-1.29
-1.54
-2.54
-3.46
-3.56
-3.01
-4.37
-1.50
-4.08
-0.29
EPS, diluted
-1.29
-1.54
-2.54
-3.46
-3.56
-3.01
-4.37
-1.50
-4.08
-0.29
Shares, basic (weighted)
37
38.8
40.4
42.3
47.5
59.8
63.8
74.3
78.9
89.2
Shares, diluted (weighted)
38.3
38.8
40.4
42.3
47.5
59.8
63.8
74.3
78.9
89.2
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
41
99.4
103
62.4
84.8
166
61.7
58.2
58.5
93
Short-term investments
123
208
209
272
262
286
249
145
Receivables
18.5
13.9
12.7
18
15.9
15.9
16.6
21.2
27.1
80.1
Inventory
2.83
5.35
5.62
6.08
7.61
7.31
4.52
9.41
41.9
36.2
Other current assets
4.83
3.11
4.14
5.02
8.14
6.72
12
19.3
12.7
28.8
Total current assets
332
326
496
429
410
583
486
617
417
438
Property, plant and equipment
2.59
3.23
3.15
2.89
9.42
11.1
9.05
7.48
5.34
4.02
Lease right-of-use assets
7
25.7
23.2
21
18.1
14.3
10.6
Goodwill
0.94
0.94
0.94
0.94
0.9
0.9
0.8
0.8
0.8
Intangible assets
182
185
187
157
154
148
97.1
104
104
114
Long-term investments
78
160
127
5.02
125
103
260
84.4
Other non-current assets
7.36
5.56
7.71
14.7
7.81
11.1
10.7
10.7
18.2
8.88
Total assets
525
520
709
605
607
777
673
789
594
605
Accounts payable
7.52
18.9
6.95
26.6
12.1
15.1
17.3
41.7
23.5
24.8
Accrued liabilities
33.3
36
49.7
51.7
56.8
75.2
95.7
119
86
126
Deferred revenue
0
16.3
12
7.1
2.82
Total current liabilities
83.3
85.7
105
95.4
92.7
124
142
178
201
160
Lease liabilities
7.39
28.3
31.5
27.5
22.6
17.2
11.1
Other non-current liabilities
4.01
2.47
17.5
20.9
12.2
12.3
9.39
10.3
6.8
7.6
Total liabilities
218
227
391
384
396
475
630
588
535
490
Paid-in capital
421
472
590
637
798
1,069
1,060
1,328
1,506
1,589
Retained earnings
-113
-178
-270
-416
-586
-766
-1,014
-1,126
-1,447
-1,473
Other comprehensive income
-0.49
-1.02
-1.53
0.73
-0.9
-0.56
-2.91
-1.46
-0.08
-1.19
Shareholders' equity
308
293
318
221
211
302
42.9
201
59.1
115
Total equity
308
293
318
221
211
302
42.9
201
59.1
115
Total liabilities and equity
525
520
709
605
607
777
673
789
594
605
Shares outstanding
37.9
39.4
41.4
43.1
52.2
62.5
64.3
75.4
87.5
90.9
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-47.9
-59.7
-103
-146
-169
-180
-278
-111
-322
-25.5
Depreciation and amortization
16.1
17.8
18.7
20.4
24.6
12.7
20.7
38.5
43.6
60.7
Stock-based compensation
29.1
26.9
19.8
21.1
23.6
29.6
38.1
44.2
36.9
44.9
Deferred income tax
-22.7
-6.43
0
0
0
0
0
0
0
0
Change in receivables
-6.09
4.95
0.15
-5.18
2.3
0.85
-1.06
-11.3
-6
-27.8
Change in inventory
-0.57
-1.71
-2.77
-1.96
-5.07
0.12
-1.21
-39.4
-3.77
5.02
Change in payables
-2.92
2.06
-2.71
9.26
-6.04
2.77
2.31
24.8
-17.6
-0.09
Cash from operations
-3.44
7.4
-25
-58.2
-42.7
-14.8
-186
-280
-237
37.8
Capital expenditures
-1.43
-0.89
-0.73
-0.2
-6.77
-5.1
-0.19
-0.67
Acquisitions
-0.62
0
0
0
-95.3
0
0
Purchases of investments
0
-102
-331
-224
-215
-547
-385
-444
-126
-237
Sales and maturities of investments
160
115
163
259
274
434
382
Cash from investing
10.4
45.6
-203
19.9
-61.3
-138
-32.6
55.8
99.3
27.9
Debt repaid
0
0
-40.2
0
0
Stock issued
0
0
10.6
1.62
3.9
189
0
191
135
0
Share buybacks
0
Cash from financing
-3.85
5.45
232
-2.08
128
232
118
219
139
-33.5
Exchange rate effect
0.12
-0.06
-0.14
-0.01
-1.31
1.71
-2.79
1.98
-0.91
2.29
Net change in cash
3.2
58.4
3.48
-40.4
22.3
81
-104
-3.51
0.36
34.5
Free cash flow
-4.87
6.52
-25.7
-58.4
-49.5
-19.9
-186
-281
Interest paid
2.07
2.07
1.88
7.67
6.9
7.33
10.2
8.84
8.84
8.84
Income taxes paid
7.93
7.17
0.22
0.66
-3.37
-16.4
1
0.58
0.45
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $59.44 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
98.6%
Gross profit / revenue.
Operating margin
-6.8%
Operating income / revenue.
EBITDA margin
3.9%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-11.3%
Pre-tax income / revenue.
Net margin
-7.4%
Net income / revenue.
Operating cash flow margin
15.7%
Cash from operations / revenue.
Return on equity (ROE)
-177.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-5.4%
Net income / average total assets.
R&D / revenue
38.4%
Research and development expense / revenue.
SG&A / revenue
61.6%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
10.3%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
10.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
110.5%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
64.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
19.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
113.1%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
66.0%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
20.1%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
94.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
38.9%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-11.5%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
1.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-3.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-0.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
13.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
11.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
13.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.05x
Current assets / current liabilities.
Quick ratio
2.46x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.93x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.47
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$6.33
Revenue / diluted weighted shares.
Operating cash flow per share
$0.99
Cash from operations / diluted weighted shares.
Book value per share
$0.26
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
9.48x
Market cap / revenue.
P/B
228x
Market cap / shareholders' equity. Only when equity is positive.
P/OCF
60.4x
Market cap / cash from operations, when positive.
EV/Sales
8.98x
Enterprise value / revenue.
EV/EBITDA
232x
Enterprise value / EBITDA, when both are positive.
Earnings yield
-0.8%
Net income / market cap (the inverse of P/E).
What was Travere Therapeutics, Inc.'s revenue in fiscal 2025?
Travere Therapeutics, Inc. reported revenue of $490.7M for fiscal 2025, 110.5% higher than the year before.
Was Travere Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $25.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.